RxDoctor Payments Data

Fadhil Hussein, MD

Cardiovascular Disease · Toledo, OHNPI 1992770739

Payments from drug & device makers

$5,036in general payments, 2019–2025

Across 298 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$670
  • Amarin Pharma, Inc.$655
  • Novartis$438
  • Actelion Pharmaceuticals US, Inc.$317
  • Amgen$291
  • Abbott$284
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,83896%
  • Education$1984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,036 in reported general payments places this provider in the 65th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$397,932
Medicare patients
1,218
Services billed
5,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban709$711,632
Repatha SureclickEvolocumab313$241,705
EntrestoSacubitril/Valsartan169$191,663
XareltoRivaroxaban150$160,253
Praluent PenAlirocumab77$40,548
Metoprolol Succinate1,968$30,727
MultaqDronedarone Hcl22$30,596
Colesevelam Hcl75$28,565
FarxigaDapagliflozin Propanediol21$22,507
Ranolazine ErRanolazine183$20,312
BrilintaTicagrelor27$18,776
Rosuvastatin Calcium1,146$18,562
Amiodarone Hcl571$16,369
Losartan Potassium1,157$13,476
Digoxin849$13,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$162$711,632709 claims
NovartisEntresto$438$191,663169 claims
Johnson & JohnsonXarelto$670$160,253150 claims
AstraZenecaFarxiga, Brilinta$228$41,28348 claims
Sanofi-aventis U.S. LLCMultaq$264$30,59622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →